Impact of prophylactic post-transplant ponatinib administration on outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

The impact of post-transplant ponatinib maintenance therapy on outcomes after allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia remains still unknown. This retrospective study suggested that survival in the ponatinib group was better than that in non-ponatinib group and ponatinib maintenance therapy was safety. The post-transplant ponatinib maintenance strategy might be promising.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 14, 2020 Category: Hematology Authors: Satoru Nanno, Kana Matsumoto, Mika Nakamae, Hiroshi Okamura, Mitsutaka Nishimoto, Asao Hirose, Hideo Koh, Yasuhiro Nakashima, Takahiko Nakane, Kunihiko Morita, Masayuki Hino, Hirohisa Nakamae Tags: Original Study Source Type: research